Results 171 to 180 of about 23,984,619 (356)

The Hierarchical Hidden Markov Model: Analysis and Applications

open access: yesMachine-mediated learning, 1998
Shai Fine, Y. Singer, Naftali Tishby
semanticscholar   +1 more source

Stagewise crop yield prediction with multisource functional indices

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract Index insurance design involves integrating weather data, soil moisture, phenology information, and satellite imagery, which presents challenges in data fusion. This article addresses the modelling of multisource functional indices of varying lengths by constructing a stagewise ensemble of sequential models.
Jing Zou, Ostap Okhrin
wiley   +1 more source

The hidden Markov model and its applications in bioinformatics analysis. [PDF]

open access: yesGenes Dis
Ma Y   +17 more
europepmc   +1 more source

A goodness‐of‐fit test for regression models with discrete outcomes

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract Regression models are often used to analyze discrete outcomes, but classical goodness‐of‐fit tests such as those based on the deviance or Pearson's statistic can be misleading or have little power in this context. To address this issue, we propose a new test, inspired by the work of Czado et al.
Lu Yang   +2 more
wiley   +1 more source

Fourier Mass Lower Bounds for Batchelor‐Regime Passive Scalars

open access: yesCommunications on Pure and Applied Mathematics, EarlyView.
ABSTRACT Batchelor predicted that a passive scalar ψν$\psi ^\nu$ with diffusivity ν$\nu$, advected by a smooth fluid velocity, should typically have Fourier mass distributed as |ψ̂ν|2(k)≈|k|−d$|\widehat{\psi }^\nu |^2(k) \approx |k|^{-d}$ for |k|≪ν−1/2$|k| \ll \nu ^{-1/2}$.
William Cooperman, Keefer Rowan
wiley   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy